John Oyler Sells 61,397 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 61,397 shares of the business’s stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99. Following the transaction, the chief executive officer owned 9,180 shares of the company’s stock, valued at $2,916,210.60. This represents a 86.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The stock was sold at an average price of $312.25, for a total value of $15,086,671.00.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total value of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Down 1.0%

Shares of BeOne Medicines stock opened at $327.21 on Thursday. The firm has a market capitalization of $35.90 billion, a PE ratio of 73.20 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The firm’s 50-day moving average price is $293.14 and its 200 day moving average price is $309.42. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion during the quarter. On average, sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. EFG International AG acquired a new position in shares of BeOne Medicines during the fourth quarter worth $25,000. Leonteq Securities AG acquired a new stake in BeOne Medicines during the 4th quarter worth $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines during the second quarter worth about $35,000. CWM LLC increased its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new stake in BeOne Medicines in the fourth quarter valued at approximately $61,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

ONC has been the subject of several recent analyst reports. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 3rd. Morgan Stanley reiterated an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday, July 17th. Truist Financial boosted their price objective on BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Finally, Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $394.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.